Results 181 to 190 of about 4,166,507 (358)

Biopharmaceutical study of the hepato-biliary transport of drugs. IV. Development of the method to investigate the process of the active secretion of drugs from the hepatocytes into the bile canaliculi and its application to the biliary excretion of organic anions in rat.

, 1976
Kanji Takada, Yuji Tokunaga, Shozo Muranishi   +2 more
openalex   +2 more sources

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Has FDA's Drug Development Tools Qualification Program Improved Drug Development? [PDF]

Ther Innov Regul Sci
Yang F, Bousnina I, Madej A, Kalamegham R.   +3 more
europepmc   +1 more source

Study on the Development of Diltiazem HCl Loaded Colonic Drug Delivery Systems (CDDS) Using Various Polymers and Characterization of their Release Profiles by <i>In Vitro</i> Dissolution Studies

, 1970
Maheen Islam, Jakir Ahmed Chowdhury, Shirajum Monira Tania   +2 more
openalex   +2 more sources

The Anonymity of Drug Development [PDF]

, 1986
John C. Somberg
openalex   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Advancing drug development with "Fit-for-Purpose" modeling informed approaches. [PDF]

J Pharmacokinet Pharmacodyn
Sheng J, Zhang T.
europepmc   +1 more source

The use of cell kinetics in the development of drug combinations

, 1979
Frederick A. Valeriote
openalex   +1 more source

The colony assay in-vitro as a procedure to reduce animal testing in the development of new anticancer drugs [PDF]

, 1986
H.H. Fiebig, J. Schmid
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source